COYA
Coya Therapeutics Inc

1,045
Mkt Cap
$121.15M
Volume
156,782.00
52W High
$8.29
52W Low
$4.65
PE Ratio
-5.25
COYA Fundamentals
Price
$5.98
Prev Close
$5.79
Open
$5.97
50D MA
$6.06
Beta
1.17
Avg. Volume
268,108.91
EPS (Annual)
-$0.9765
P/B
3.55
Rev/Employee
$444,257.63
Loading...
Loading...
News
all
press releases
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Rating of "Moderate Buy" by Brokerages
Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat reports. One...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from Chardan Capital
Chardan Capital restated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Friday...
MarketBeat·4d ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised Coya Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·4d ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Stock Price Expected to Rise, BTIG Research Analyst Says
BTIG Research increased their price objective on Coya Therapeutics from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday...
MarketBeat·6d ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from D. Boral Capital
D. Boral Capital reissued a "buy" rating and set a $15.00 price target on shares of Coya Therapeutics in a research note on Wednesday...
MarketBeat·7d ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Releases Earnings Results, Misses Estimates By $0.12 EPS
Coya Therapeutics (NASDAQ:COYA - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus...
MarketBeat·7d ago
News Placeholder
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·8d ago
News Placeholder
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced...
Business Wire·16d ago
News Placeholder
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·24d ago
News Placeholder
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·27d ago

Latest COYA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.